<DOC>
	<DOCNO>NCT01900431</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy sarilumab week 16 patient non-infectious uveitis ( NIU ) . Secondary Objectives : To evaluate change best correct visual acuity ( BCVA ) . To evaluate safety subcutaneous sarilumab patient NIU . To evaluate change macular edema . To evaluate change sign ocular inflammation . To evaluate effect retinal vessel leakage . To evaluate effect sarilumab reduce concomitant immunosuppressant therapy . To evaluate change ocular inflammation anterior chamber . To evaluate pharmacokinetics sarilumab NIU patient . To evaluate immunogenicity anti-drug antibody ( ADA ) .</brief_summary>
	<brief_title>Phase II Study Analyze Sarilumab Non-Infectious Uveitis</brief_title>
	<detailed_description>The total duration per patient 58 week , include 2 week screening period , 16 week principal treatment period , 34 week extension treatment period ( open label treatment period ) , 6 week last treatment administration . Non-responder patient , observe within first 16 week , offer treat open-label sarilumab . Patients treat 34 extra week ( 18 extra injection ) .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Inclusion criterion : ≥18 year age . Noninfectious intermediate , posterior , panuveitis study eye . Active disease screen evidence activity within 3 month prior screen visit . Following approval Amendment 2 , patient `` active disease '' define enrol study . Starting oral prednisone dose must great equal 15 mg/day less 80 mg/day . At screening , patient must receive oral prednisone ( ≥15 mg &lt; 80 mg/day [ equivalent oral corticosteroid ] ) single immunosuppressive therapy combination Methotrexate ( MTX ) ( ≤ 25 mg/week ) orally intravenously intra muscular subcutaneous ) . Patients receive one several follow therapy : Azathioprine ( ≤2.5 mg/kg/day ) , Mycophenolate mofetil ( ≤2g daily , orally ) , Cyclosporine ( ≤4 mg/kg daily , orally ) , Tacrolimus ( ≤4 mg daily , orally ) . The dos may increase least 4 week prior randomization visit . At randomization , patient receive oral prednisone ( ≥15 mg &lt; 80 mg/day [ equivalent oral corticosteroid ] ) single immunosuppressive therapy combination methotrexate ( MTX ) ( ≤ 25 mg/week ) orally intravenously intra muscular subcutaneous ) . Azathioprine , mycophenolate mofetil , cyclosporine tacrolimus permanently discontinue least 48 hour prior first study treatment injection , long per Investigator 's judgment . These immunomodulatory therapy ( IMTs ) permit anytime treatment period . Signed write informed consent . Exclusion criterion : Patient bestcorrected visual acuity bad 20 ETDRS letter least one eye . Patient confirm suspected uveitis infectious etiology uveitis traumatic etiology . Patient primary diagnosis anterior uveitis . Prior treatment antiIL6 IL6R antagonist therapy , include tocilizumab sarilumab . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>